Are you ready to better understand and predict drug-induced liver injury before it reaches the clinic?

Then join us for an interactive webinar introducing DILIsym® 11, the latest evolution of the industry’s leading quantitative systems toxicology (QST) platform. Designed to predict clinical liver safety outcomes, DILIsym integrates in vitro mechanistic data with physiologically based pharmacokinetic (PBPK) predictions of liver drug concentrations.

In this webinar, you’ll learn about:

• New Predictive Mechanisms: Explore how the addition of T cell–mediated adaptive immune responses advances immune-related DILI simulation.
• Expanded SimPops: Model pediatric populations and diverse patient profiles to support safer, more inclusive drug development.
• Enhanced Sub-Models: Discover refinements in the simulation of cholestatic injury and other liver injury types, enabling more accurate scenario testing.

The webinar will also feature a live software demonstration and an interactive Q&A. Don’t miss this opportunity to see the latest advances in liver safety science and software. Register now.

Presenter: 

• Kyunghee Yang – Associate Director/Senior Principal Scientist, Scientific Staff
• Daniel J. O’Connor – Senior Director, Business Development (Moderator)